Literature DB >> 1827328

Optimal management of superficial bladder cancer.

J A Witjes1, F M Debruyne.   

Abstract

Entities:  

Mesh：

Year:  1991        PMID： 1827328     DOI： 10.1016/0277-5379(91)90541-k

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  4 in total

1.  The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma.

Authors:  I Ariel; M Sughayer; Y Fellig; G Pizov; S Ayesh; D Podeh; B A Libdeh; C Levy; T Birman; M L Tykocinski; N de Groot; A Hochberg
Journal:  Mol Pathol       Date:  2000-12

2.  Tissue disposition and plasma concentrations of idarubicin after intravesical therapy in patients with bladder tumors.

Authors:  K Mross; K Hamm; W Schultze-Seemann; K Burk; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Interferon beta enhances the natural killer activity of patients with bladder carcinoma.

Authors:  L Moltó; J Carballido; L Manzano; C Olivier; P Lapeña; M Alvarez-Mon
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

4.  Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation.

Authors:  L Molto; M Alvarez-Mon; J Carballido; L Manzano; C Guillen; A Prieto; C Olivier; M Rodriguez-Zapata
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.